AstraZeneca closes India R&D shop

Share this article:

AstraZeneca is laying off 168 pharmaceutical employees at the Avishkar R&D site in Bangalore, India. The company said in a statement that the move is in line with its shift to focus on three core areas—oncology; cardiovascular and metabolic; and respiratory, inflammation and autoimmunity.

The Avishkar operation was focused on conditions including TB, malaria and neglected tropical diseases. AstraZeneca will continue to develop Phase-II TB medication AZD5847. The company said it will continue to make its compound library available to open-innovation partnerships.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.